Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775748 · ClinicalTrials.gov registry record · NA
Effect of Concord Grape Juice on Endothelial Function
A NA study, sponsored by Boston University.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
NCT01775748: Completed NA study, sponsored by Boston University.
NCT01775748 is a NA study that has completed, run by Boston University. The registered enrollment target is 77 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775748, a NA study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
Study Summary
The study will compare Concord grape juice to a beverage that contains no grape flavonoids, but has a similar appearance and taste (placebo juice). A total of 60 overweight and obese participants over age 50 will be enrolled. Each participant will drink each beverage for 4 weeks with a 2-week rest period between two beverage consumption periods. The order of beverages (grape juice first or placebo juice first) will be randomized. The investigators will use ultrasound to measure brachial artery flow-mediated dilation, a measure of endothelial vasodilator function. The investigators will also collect blood samples to further assess the cardiovascular effects of grape juice. The aim of the study is to determine whether Concord grape juice improves endothelial function in patients at risk who do not have cardiovascular disease and may provide information that would guide dietary recommendations. The results may also be used by the sponsor to substantiate claims and labeling of their product.
Primary Outcome
Endothelial function will be assessed as brachial artery flow-mediated dilation using vascular ultrasound
Interventions
- OTHER Active Concord Grape Juice 12 oz per day
- OTHER Placebo Grape Juice 12 oz per day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2014-03-19 |
| Phase | NA |
What the finished NCT01775748 record still lists
NCT01775748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Active Concord Grape Juice 12 oz per day is the first listed.
NCT01775748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01775748 about?
NCT01775748 is a clinical study titled "Effect of Concord Grape Juice on Endothelial Function". The study will compare Concord grape juice to a beverage that contains no grape flavonoids, but has a similar appearance and taste (placebo juice). A total of 60 overweight and obese participants over age 50 will be enrolled. Each participant will drink each beverage for 4 weeks with a 2-week rest p...
What is the current status of trial NCT01775748?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2013-01-01. Estimated completion is 2014-03-19.
What interventions are being tested in trial NCT01775748?
The interventions under investigation include: Active Concord Grape Juice 12 oz per day (OTHER), Placebo Grape Juice 12 oz per day (OTHER).
Who is sponsoring clinical trial NCT01775748?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01775748's enrollment target sits among peer trials
77 1062nd of 2000 higher than 939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI